New shot could simplify schizophrenia treatment

NCT ID NCT06253546

Completed Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 1 trial tests a single injection of TV-44749, an extended-release form of olanzapine, in Chinese adults with stable schizophrenia. The study aims to check safety, tolerability, and how the drug moves through the body. Participants receive one of three doses of the injection or continue oral olanzapine for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TV-44749 (extended-release injectable olanzapine)
What this could lead to: If successful, this could provide a longer-lasting treatment option for schizophrenia, potentially reducing the need for daily pills.
What could go wrong: This is an early phase 1 trial with only 24 participants, so safety and effectiveness are not yet established. Side effects may occur, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Teva Investigational Site 88046

Shanghai, 200030, China
Teva Investigational Site 88047

Guangzhou, 510370, China
Teva Investigational Site 88048

Beijing, 100191, China
Teva Investigational Site 88049

Beijing, 100088, China
Teva Investigational Site 88050

Wuhan, 430022, China
Teva Investigational Site 88056

Xi'an, 710061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.